Blueprint became a Sanofi deal story
- Blueprint’s standalone story was replaced by Sanofi’s acquisition agreement announced on June 2, 2025.
- AYVAKIT/AYVAKYT was the main product, with Q1 2025 net product revenue of $149.4 million.
- The company raised 2025 AYVAKIT revenue guidance to $700 million to $720 million before the deal news took over.
- The bull case is simple: Sanofi closes the deal and shareholders receive the agreed deal value.
- The bear case is deal failure, which would put valuation back on Blueprint’s standalone drug sales and pipeline risk.
A merger, not a normal stock call
Blueprint Medicines is no longer mainly a bet on how fast AYVAKIT grows or whether the next pipeline drug works. The key event was Sanofi’s agreement to acquire the company, announced on June 2, 2025. That changed the question from “how good is this biotech?” to “does the deal close, and when?”
The bull case is that the deal clears its closing steps without a serious delay. In that case, the return for shareholders is mostly tied to the agreed purchase terms, not to a fresh view of Blueprint’s long-term earnings power.
The bear case is that the deal fails because of regulators, deal conditions, or another surprise. If that happened, Blueprint would likely trade again on its standalone fundamentals. Those fundamentals improved in Q1 2025, but the internal view is that the standalone value would likely sit below the acquisition price.
A later Sanofi release says the acquisition closed on July 18, 2025, and Blueprint became an indirect wholly owned Sanofi subsidiary. That supports the deal-close bull case, but this page keeps the internal thesis frame focused on deal completion because that is the latest approved thesis state on file.
One drug paid the bills
Blueprint was a fully integrated biotech. That means it discovered drugs, ran clinical trials, and sold approved medicines itself. Its science focused on kinase inhibition and targeted protein degradation, which are ways to block disease-driving proteins inside cells.
Most revenue came from AYVAKIT/AYVAKYT, also called avapritinib. In Q1 2025, net product revenue was $149.4 million, with $129.4 million from the United States and $20.0 million from the rest of the world.
Blueprint also had collaboration, license, and royalty paths with partners such as CStone and Rigel. Those helped monetize parts of the portfolio, but the company did not break those into formal operating segments in the same way it showed product revenue by geography.
The main break point was concentration. If AYVAKIT growth slowed, reimbursement became tougher, or a safer competitor won doctors over, Blueprint’s standalone case would weaken fast.
Mast cell drugs led the story
AYVAKIT/AYVAKYT
This was Blueprint’s main approved drug and main revenue source. It treats systemic mastocytosis and certain GIST tumors with a PDGFRA exon 18 mutation.
Indolent systemic mastocytosis use
This was the key growth use for AYVAKIT. The Q1 2025 filing said product revenue grew mainly because more indolent SM and advanced SM patients were on therapy.
Elenestinib, BLU-263
Elenestinib is a next-generation selective KIT inhibitor being developed for indolent systemic mastocytosis. It offered follow-on potential in Blueprint’s core mast cell franchise.
BLU-808
BLU-808 is a wild-type KIT inhibitor being developed for chronic urticaria and other allergic-inflammatory diseases. It was also tied to potential future value in the Sanofi deal structure.
BLU-222
BLU-222 is a CDK2 inhibitor. Blueprint said it was completing the Phase 1 study and de-prioritizing further investment while looking for strategic partners.
GAVRETO
GAVRETO, or pralsetinib, was no longer a core U.S. commercial focus after U.S. rights were sold to Rigel. Blueprint remained eligible for milestones and royalties.
AYVAKIT sales by geography
Blueprint did not report formal operating segments. The mix below uses Q1 2025 net product revenue from AYVAKIT/AYVAKYT, which was $129.4 million in the United States and $20.0 million in the rest of world.
What could still go wrong
Deal closing condition risk
High impact · Low oddsThe internal thesis treats Blueprint as a merger situation. If required conditions failed, the stock would have been valued again on standalone drug sales and pipeline odds. A later Sanofi release says the deal closed on July 18, 2025, so this risk appears to have resolved, but it remains the key risk in the approved thesis frame.
AYVAKIT concentration
High impact · Medium oddsBlueprint depended heavily on AYVAKIT/AYVAKYT. In Q1 2025, essentially all disclosed product revenue came from that drug. If patient starts slowed, doctors used another therapy, or payors pushed back on coverage, standalone growth would suffer.
Pipeline setback
Medium impact · Medium oddsDrug trials can fail even when early science looks strong. Elenestinib and BLU-808 needed clinical data and regulatory wins to support future value. Blueprint also de-prioritized BLU-222, which removed a near-term oncology growth path unless a partner stepped in.
Competition in mast cell and oncology markets
Medium impact · Medium oddsLarge drug companies and smaller biotechs are working in related areas. Competitors such as Novartis, Cogent Biosciences, AstraZeneca, and Pfizer could make drugs that look safer, work better, or cost less. That would pressure Blueprint’s standalone sales and pricing power.
Patent and exclusivity challenges
Medium impact · Low oddsBlueprint’s moat depended on patents around its approved and pipeline therapies. If key patents were challenged or narrowed, generic or copycat risk could rise over time. This matters more in a standalone case than in a completed merger case.
In one breath
What does Blueprint Medicines do?
Blueprint Medicines developed targeted medicines for diseases driven by specific cell signals. Its main approved drug was AYVAKIT/AYVAKYT for systemic mastocytosis and certain GIST tumors.
Why did the Blueprint thesis change?
The thesis changed because Sanofi agreed to acquire Blueprint on June 2, 2025. After that, the main investor question became whether the deal would close instead of whether Blueprint could grow alone.
Where did Blueprint’s revenue come from?
Most revenue came from AYVAKIT/AYVAKYT. In Q1 2025, net product revenue was $149.4 million, split between $129.4 million in the United States and $20.0 million in the rest of world.
What is the biggest risk in the internal view?
The biggest risk was deal failure. If the Sanofi acquisition had not closed, Blueprint would likely have been valued on AYVAKIT growth, pipeline risk, competition, and patent protection.